睿知中国医院研究地图
候选清单

正在招募肺癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 10 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 80 岁;性别:不限

    登记记录的入选字段

  2. Has histologically confirmed locally advanced (Stage IIIB/C) or metastatic (Stage IV) non-squamous NSCLC

    入选标准第 2 条

    Has KRAS G12C mutation confirmed by central laboratory

    入选标准第 4 条

  3. Male and female subjects of reproductive potential must agree to use effective contraception during and for 6 months after treatment

    入选标准第 10 条

    Prior treatment with KRAS G12C inhibitors, FAK inhibitors, or immune checkpoint inhibitors

    排除标准第 3 条

  4. ECOG performance status of 0-1

    入选标准第 7 条

  5. Has another known driver mutation with approved targeted therapy (e.g., EGFR, ALK, ROS1)

    排除标准第 4 条

  6. Has at least one measurable lesion per RECIST v1.1

    入选标准第 6 条

  7. Has history of another malignancy within 5 years, except those curatively treated and considered low risk (e.g., basal cell carcinoma, cervical carcinoma in situ)

    排除标准第 6 条

    Has known active hepatitis B, hepatitis C, or HIV infection

    排除标准第 8 条

  8. Pregnant or breastfeeding women

    排除标准第 10 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07174908,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Able and willing to provide informed consent and comply with study requirements
  2. Has histologically confirmed locally advanced (Stage IIIB/C) or metastatic (Stage IV) non-squamous NSCLC
  3. Aged 18-80 years at the time of consent
  4. Has KRAS G12C mutation confirmed by central laboratory
  5. Has not received prior systemic therapy for advanced or metastatic NSCLC
  6. Has at least one measurable lesion per RECIST v1.1
  7. ECOG performance status of 0-1
  8. Has adequate organ function
  9. Life expectancy ≥3 months in the opinion of the Investigator
  10. Male and female subjects of reproductive potential must agree to use effective contraception during and for 6 months after treatment

排除标准:Exclusion Criteria:

  1. Has other histological subtypes of NSCLC (e.g., small cell or neuroendocrine)
  2. Has active or untreated CNS metastases or carcinomatous meningitis
  3. Prior treatment with KRAS G12C inhibitors, FAK inhibitors, or immune checkpoint inhibitors
  4. Has another known driver mutation with approved targeted therapy (e.g., EGFR, ALK, ROS1)
  5. Has uncontrolled cardiovascular disease, active severe infection, interstitial lung disease, or autoimmune disease requiring systemic therapy
  6. Has history of another malignancy within 5 years, except those curatively treated and considered low risk (e.g., basal cell carcinoma, cervical carcinoma in situ)
  7. Has gastrointestinal conditions that may interfere with absorption of oral drugs (if applicable)
  8. Has known active hepatitis B, hepatitis C, or HIV infection
  9. Has received a live vaccine within 30 days before first dose of study drug
  10. Pregnant or breastfeeding women
  11. Has psychiatric or substance abuse disorders that would interfere with study compliance
  12. Is participating in another interventional clinical study
  13. Any condition that, in the opinion of the Investigator, would interfere with participation or study results

引自 ClinicalTrials.gov, NCT07174908, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07174908,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07174908